CELEBRATE — Zalunfiban at First Medical Contact for STEMI

1. Publication

• Title: Zalunfiban at First Medical Contact for ST-Elevation Myocardial Infarction (CELEBRATE)
• Acronym: CELEBRATE
• Year & Journal: NEJM Evidence, epublished November 10, 2025 (print: 2026;5(1):EVIDoa2500268)
• Citation: van't Hof AWJ, Gibson CM, Rikken SAOF, et al; CELEBRATE Trial Investigators. Zalunfiban at First Medical Contact for ST-Elevation Myocardial Infarction. NEJM Evid. 2026;5(1):EVIDoa2500268. doi:10.1056/EVIDoa2500268

2. Context & Rationale

Background: Primary PCI is the reference STEMI treatment, but its effectiveness decreases with time to catheterization. Early antiplatelet therapy could theoretically inhibit thrombus progression and facilitate reperfusion before PCI, but randomized trials of oral P2Y12 inhibitor pretreatment have not shown a reperfusion benefit. Zalunfiban is a novel subcutaneous glycoprotein IIb/IIIa inhibitor designed for rapid, field-deployable administration at first medical contact (home, ambulance, or ED) — reviving a drug class largely set aside for over a decade due to hospital-infusion logistics.

Research Question/Hypothesis: In patients with suspected STEMI, does subcutaneous zalunfiban administered at first medical contact improve preintervention infarct-related artery patency and reduce a 30-day hierarchical composite clinical endpoint compared with placebo?

Why This Matters: Tests whether a field-ready, rapidly-administered antiplatelet strategy can succeed where oral P2Y12 pretreatment trials failed, potentially reviving upstream GPIIb/IIIa inhibition as an effective STEMI treatment strategy.

3. Design & Methods

• Study Type: International, randomized, double-blind, placebo-controlled, phase 3 trial
• Setting & Centers: International (presented at AHA 2025, New Orleans)
• Population:
• Inclusion: Patients with suspected STEMI, symptoms <4 hours
• Exclusions: Not detailed in available trial text
• Intervention: Single subcutaneous injection of zalunfiban, 0.11 mg/kg or 0.13 mg/kg, at first medical contact (home, ambulance, or ED)
• Comparator: Placebo
• Randomization: 1:1:1, 2467 patients (853 zalunfiban 0.11mg/kg, 818 zalunfiban 0.13mg/kg, 796 placebo)
• Blinding: Double-blind
• Statistical Power & Follow-Up: Primary efficacy endpoint: hierarchical proportional odds model ranking 7 endpoints worst-to-best (all-cause death, stroke, recurrent MI, acute stent thrombosis, new-onset/rehospitalization for heart failure, larger infarct size, or no endpoint) through 30 days. Primary safety endpoint: severe/life-threatening bleeding per GUSTO criteria.

4. Key Results

2467 patients randomized.

5. Internal Validity Assessment

• Randomization & Allocation: International, 1:1:1 randomization (two zalunfiban doses plus placebo); specific concealment mechanics not detailed in available trial text.
• Protocol Adherence & Separation: Field administration at first medical contact (home, ambulance, ED) achieved as designed; angiographic patency data (corrected TIMI frame count) confirms genuine on-target biological effect.
• Blinding & Detection Bias: Full double-blind, placebo-controlled design — strong protection against both performance and detection bias, notable given the prehospital field-administration setting.
• Missing Data & Sensitivity Analyses: Not detailed in available trial text.
• Overall Internal Validity Conclusion: Strong — large (2467-patient), double-blind, placebo-controlled, adequately powered trial with a confirmed on-target biological effect (angiographic patency) supporting the clinical composite result; the hierarchical composite methodology appropriately weighs harder outcomes more heavily than softer ones.

6. External Validity Assessment

• Population Representativeness: International population with suspected STEMI within 4 hours of symptom onset — broadly representative of the STEMI population for whom prehospital treatment decisions are made.
• Practice Context: Designed specifically for field/prehospital administration (subcutaneous injection, no infusion pump needed) — a genuine logistical advantage over prior IV GPIIb/IIIa inhibitors requiring hospital-based infusion, making this broadly deployable in EMS systems.
• Overall External Validity Conclusion: Good — the subcutaneous, field-ready formulation specifically addresses the practical deployment barrier that limited prior GPIIb/IIIa inhibitor use, supporting genuine real-world applicability if approved.

7. Strengths & Limitations

Strengths:

• Large (2467-patient), double-blind, placebo-controlled, international phase 3 trial
• Novel field-deployable subcutaneous formulation solving the practical deployment barrier of prior IV GPIIb/IIIa inhibitors
• Confirmed on-target angiographic biological effect (faster coronary flow, improved TIMI frame count) supporting the clinical composite result
• No excess severe/life-threatening bleeding despite increased mild-to-moderate bleeding

Limitations:

• Industry-funded (CeleCor Therapeutics) trial
• Increased mild-to-moderate bleeding is a real tradeoff, even without excess severe bleeding
• The hierarchical composite primary endpoint, while methodologically appropriate, combines hard (death, stroke) and softer (larger infarct size) components — accompanying editorial specifically calls for confirmation with hard clinical outcomes in future trials before guideline change
• Not yet reflected in current STEMI treatment guidelines (AHA 2025/ESC 2023 still recommend oral DAPT as standard)

8. Interpretation & Practice Impact

• Clinical Implications: Supports further development of zalunfiban as prehospital adjunctive antiplatelet therapy for suspected STEMI, given demonstrated improved angiographic patency and a favorable overall clinical composite result, but current guidelines have not yet incorporated this investigational therapy.
• Mechanistic Coherence: The improved angiographic patency (faster coronary flow, better TIMI frame count) provides direct biological confirmation that the drug is achieving its intended pharmacological effect — supporting the clinical composite finding as a genuine treatment effect rather than a chance result.
• Systems-Level Takeaway: If confirmed by future hard-outcome trials, could reestablish upstream GPIIb/IIIa inhibition as a viable prehospital STEMI treatment strategy, made newly practical by the subcutaneous formulation; the manufacturer plans an FDA marketing authorization application in early 2026.

9. Controversies & Subsequent Evidence

• Editorial Commentary: An accompanying editorial (d'Entremont, Jolly) states CELEBRATE "brings back a treatment option that has been set aside for over a decade by transforming a hospital-based infusion into a field-ready subcutaneous injection," while explicitly cautioning that "if subsequent randomized controlled trials confirm its effectiveness for hard clinical outcomes, similar agents could reestablish GPIIb/IIIa inhibition" — signaling that further confirmatory trials with harder outcomes are needed before this becomes standard practice.
• Guideline Integration: Current guidelines (AHA 2025, ESC 2023) still recommend early oral DAPT as standard; zalunfiban remains investigational pending larger, mortality-focused confirmatory trials and regulatory approval.

10. Summary & Executive Takeaway

Summary: CELEBRATE randomized 2467 patients with suspected STEMI (symptoms <4h) to subcutaneous zalunfiban (2 doses) or placebo at first medical contact. The 30-day hierarchical composite endpoint significantly improved with zalunfiban (adjusted OR 0.79, 95% CI 0.65-0.98, P=0.028), with faster angiographic reperfusion, no excess severe bleeding, but increased mild-to-moderate bleeding.

Overall Takeaway: Zalunfiban offers a novel, field-deployable subcutaneous antiplatelet strategy that improves early reperfusion and a hierarchical composite outcome in suspected STEMI — a genuinely promising revival of upstream GPIIb/IIIa inhibition made practical by its subcutaneous formulation, though confirmatory trials with harder clinical outcomes are needed before guideline incorporation, per the accompanying editorial's explicit caution.

11. Bibliography

• d'Entremont MA, Jolly SS. Subcutaneous Glycoprotein IIb/IIIa Inhibitor for ST-Elevation Myocardial Infarction — Teaching an Old Drug New Tricks [editorial]. NEJM Evid. 2026;5(1).